此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis

2026年9月28日 更新者:Incyte Corporation

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis

This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with impaired renal function and participants on hemodialysis.

研究概览

地位

尚未招聘

干预/治疗

研究类型

介入性

注册 (估计的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Incyte Corporation Call Center (US)
  • 电话号码:1.855.463.3463
  • 邮箱:medinfo@incyte.com

研究联系人备份

  • 姓名:Incyte Corporation Call Center (ex-US)
  • 电话号码:+800 00027423
  • 邮箱:eumedinfo@incyte.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 85年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Ability to comprehend and willingness to sign a written ICF for the study.

  • Aged 18 to 85 years, inclusive, at the time of signing the ICF.

  • Severe renal impairment or ESRD based on CKD-EPI (National Kidney Foundation).

    • Participants with impaired renal function should have stable renal function (ie, those with acute changes in renal function should not be enrolled in the study).

  • Medical findings consistent with the degree of renal dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory determinations at screening or check-in (as applicable). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible.

  • BMI of 18.0 to 43.0 kg/m2 (inclusive) at screening.

  • Ability to swallow and retain oral tablets.

  • Willingness to avoid pregnancy, breastfeeding, or fathering children.

Exclusion Criteria:

  • History of uncontrolled or unstable cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, or neurological disease within 6 months before screening.

    • History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including but not limited to the following:
    • Recent myocardial infarction (within 6 months before check-in).
    • New York Heart Association Class III or IV congestive heart failure.
    • Unstable angina (within 6 months before check-in).
    • Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker).
    • Uncontrolled hypertension.
  • Participants who have a current, functioning organ transplant or are on the national transplant list and expected to receive a transplant within 3 months.

  • History of an autoimmune disease diagnosis (eg, myasthenia gravis).

  • History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg at screening, confirmed by repeat testing).

  • Participants who have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.

  • Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).

  • History of malignancy within 5 years before screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.

  • Current or recent (within 3 months before screening) clinically significant GI disease or surgery (including cholecystectomy [< 2 months]; excluding appendectomy and hernia repair) that could affect the absorption of study drug.

  • Confirmed resting pulse rate (up to 2 consecutive measurements) < 40 bpm or > 100 bpm at screening.

  • Participants with laboratory values outside the accepted range for participants with severe renal impairment or ESRD at screening.

  • Any major surgery within 4 weeks before screening. Note: This does not include procedure for HD.

  • Blood transfusion within 4 weeks before check-in (Day -1).

  • Chronic or current active infectious disease (including latent tuberculosis) requiring systemic antibiotic, antifungal, or antiviral treatment.

  • Positive test result for HBV, HCV, or HIV. Upon testing, HBV DNA and HCV RNA must be undetectable.

    • Note 1: Participants with no prior history of HBV infection who have been vaccinated against HBV and who have a positive HBsAg antibody test as the only evidence of prior exposure may participate in the study.
    • Note 2: Participants who have cleared a prior HBV infection (defined as HbsAg negative, HBsAb positive, or HBcAb positive) may be included at the discretion of the investigator.
  • Receipt of any vaccine including but not limited to live (including attenuated), influenza, and SARS-CoV-2 vaccines within 3 months before the first dose of study drug.

  • Medical or self-reported history of alcoholism within 3 years before screening.

  • History of significant alcohol use, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females, within 3 months before screening.

  • Treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another investigational medication or current enrollment in another investigational drug study.

  • Treatment within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database Program for prohibited drugs).

  • Active infection requiring systemic therapy.

  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.

  • Known hypersensitivity or severe reaction to INCB161734, any excipients of INCB161734, or any KRAS inhibitors (refer to the IB).

  • Inability to undergo venipuncture or tolerate venous access, or inadequate veins for repeat venipuncture or venous access as determined by the investigator.

  • Tobacco or nicotine-containing product use of > 10 cigarettes per day within 1 month before screening.

  • Use of prescription drugs (including hormonal contraceptives) within 14 days before study drug administration or nonprescription medications/products (including megadose vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations as well as pre/probiotics) within 7 days of study drug administration

    • Note 1: Occasional acetaminophen, standard-dose ibuprofen, and standard-dose vitamins are permitted.
    • Note 2: Established therapy for renal disease, or the treatment of associated disorders, that has been stable for at least 7 days prior to study drug administration, is allowed if approved by the medical monitor and investigator.
  • Participants who are pregnant or lactating.

  • Excessive exercise (eg, Ironman, bi/triathlon) within 3 months before screening.

  • Participants who had a change in disease status within 30 days before screening, as documented by the participant's medical history, that is deemed clinically significant by the investigator.

  • Participants who have a history of paracentesis within 3 months prior to check-in.

  • Participants who required new medication or an increase in dose for renal disease within 3 months prior to check-in.

  • Participants who have a history of unstable diabetes mellitus (as evidenced by hemoglobin A1c ≥ 10.0%). Medications for treatment of diabetes mellitus must be reviewed and approved by the investigator and medical monitor.

  • Esophageal banding within 3 months prior to check-in or required any other treatment for GI bleeding within 6 months prior to check-in.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Group 1: Severe renal impairment

Participants with severe renal impairment will be enrolled in Group 1.

single dose administered orally

实验性的:Group 2: End-stage renal disease (ESRD)

Participants with end-stage renal disease will be enrolled in Group 2.

single dose administered orally

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
PK for plasma INCB161734: Cmax
大体时间:Up to approximately 3.5 months

Defined as the maximum plasma concentration.

Up to approximately 3.5 months
PK for plasma INCB161734: AUClast
大体时间:Up to approximately 3.5 months

Defined as the area under the concentration-time curve from time zero to time of the last quantifiable concentration.

Up to approximately 3.5 months
PK for plasma INCB161734: AUCinf
大体时间:Up to approximately 3.5 months

Defined as the area under concentration-time curve from time zero extrapolated to infinity.

Up to approximately 3.5 months

次要结果测量

结果测量
措施说明
大体时间
Number of Treatment-Emergent Adverse Events (TEAEs)
大体时间:Up to approximately 3.5 months and 30 days

Adverse events reported for the first time or worsening of a pre-existing event, occurring after first dose of study drug.

Up to approximately 3.5 months and 30 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Incyte Medical Monitor、Incyte Corporation

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月26日

初级完成 (估计的)

2027年3月30日

研究完成 (估计的)

2027年3月30日

研究注册日期

首次提交

2026年9月28日

首先提交符合 QC 标准的

2026年9月28日

首次发布 (实际的)

2026年10月2日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅